Lupus (SLE) Clinical Trial

About This Study

This clinical trial is evaluating an investigational treatment designed to help patients with systemic lupus erythematosus (SLE) who experience disease flares despite standard therapy. The study aims to determine whether this new approach can reduce flare frequency, decrease the need for corticosteroids, and improve overall disease management.

Lupus is a chronic autoimmune disease where the immune system attacks healthy tissue, causing inflammation and damage to various organs including skin, joints, kidneys, heart, and brain. Managing lupus often requires balancing disease control with medication side effects.

Learn more about lupus at Overlake Arthritis →

Who May Qualify?

You may be eligible if you:

• Have been diagnosed with systemic lupus erythematosus (SLE)
• Have had a positive ANA test
• Experience active disease symptoms despite treatment
• Are between 18 and 70 years old
• Are willing to attend study visits over approximately 9 months

Not sure if you qualify? Complete our quick eligibility screening below.

What Participation Involves

• Screening Visit: Medical history, physical exam, blood/urine tests, disease activity assessment
• Study Visits: Approximately 8-10 clinic visits over 9 months
• Study Medication: Investigational therapy (may be injection, infusion, or oral)
• Monitoring: Regular lab work and disease activity assessments

Compensation

Qualified participants receive compensation for time and travel. All study-related care is provided at no cost.

Check Your Eligibility

Answer a few quick questions to see if you may qualify. This screening is completely confidential.